Industry Press Releases

NovaBay Pharmaceuticals to Hold Second Quarter 2015 Conference Call on August 13

Friday, Jul 31, 2015
Pressreleases

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that it will report second quarter financial results after market close on Thursday, August 13. Management will hold an investment community conference call to discuss financial results and provide a company update.
                      
DATE:                Thursday, August 13, 2015
                
TIME:                 4:30 p.m. Eastern time / 1:30 p.m. Pacific time
                
DIAL IN:             866-880-4999 from within the U.S.
                         702-495-1913 from outside the U.S.
                         Enter conference identification number 82923703
                

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time August 27, 2015, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 82923703. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, and CELLERX® for the aesthetic dermatology market, cleared by the FDA as a 510(k) medical device; and its AGANOCIDE® compounds, led by AURICLOSENE™.

NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).

NovaBay has received FDA-clearance of its intelli-Case, a highly innovative, easy-to-use device for use with hydrogen peroxide disinfection solutions with soft and Rigid Gas Permeable (RGP) contact lenses.

Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website

NovaBay Contacts

For NovaBay Avenova purchasing information, please contact:
Email us
Call us: 1-800-890-0329
www.Avenova.com

Contacts

NovaBay Pharmaceuticals, Inc.
Thomas J. Paulson, 510-899-8809
Chief Financial Officer
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
Jcain@lhai.com

 

businesswire.com

Other Press Releases